AD is a common neurodegenerative disease and the most common cause of dementia in many countries. Some genetic risk factors have been studied in the sporadic cases of AD, the most important one being the genotype of the apolipoprotein E gene (ApoE) [9] [10] [11] . The codon 129 polymorphism of PRNP was also addressed as a possible risk factor in AD patients. A few studies have shown that this polymorphism may be a risk factor for AD [12] [13] [14] . Others, however, failed to confirm such association 5, 8, [15] [16] [17] [18] [19] [20] [21] . A meta-analysis concluded that codon 129 homozygosity of PRNP is a risk factor for AD in a Caucasian population 19 . More recently, data from a pathology-confirmed AD population failed to support a role of codon 129 polymorphisms as a susceptibility factor for AD 5 . AD and prion diseases are both pathogenically associated with the accumulation of misfolded protein fragments: b-amyloid protein and prion protein (PrP C ), respectively 22, 23 . Recently, the interaction of PrP C and amyloid-b oligomers has been demonstrated 24, 25 . PrP C seems to be a high-affinity binding site for amyloid-b oligomers mediating neurotoxicity 24 . Although controversies still exist, such findings brought new interest to the association of AD and PrP C 26 . We investigated the association of codon 129 polymorphism of PRNP in AD patients and age-matched, cognitively healthy control group. We also evaluated the association between this polymorphism and the cognitive performance of AD and controls. Other polymorphisms of PRNP were also evaluated as well as the potential additive effect of ApoE upon codon 129 polymorphisms in AD and controls.
METHODS
Subjects were enrolled from the Cognitive and Behavioral Unit of the Neurologic Clinic of School of Medicine of Universidade de São Paulo (USP) and from a previous study 11 . The diagnosis of probable AD followed the recommendations of the joint working group of the National Institute of Neurologic and Communicative disorders and Stroke and the AD and Related Disorders Association (NINCDS-ADRDA). The control group comprised volunteers recruited from community and nonrelated caregivers of the AD patients. Individuals with neurological and psychiatric conditions and unstable medical diseases were excluded from the control group. The cognitive evaluation of controls was done with the Folstein Mini-Mental State Exam (MMSE) and semantic verbal fluency (VF) test.
Ninety-nine patients with probable AD and 111 healthy control subjects were enrolled for analysis. The demographic data of groups are shown in Table 1 . Different subsamples were analyzed: early-onset AD (EOAD; <65 years) and lateonset AD (LOAD; ≥65 years). Control group subsamples were divided according to age at time of blood collection. The disease duration considered was the time between initial symptoms and the first cognitive evaluation.
The PRNP polymorphisms at codons 117, 129, 171 and octarepeat domain were analyzed using denaturing highperformance liquid chromatography. Technical details about this procedure as well as amplification reactions and DNA extraction have been previously described 27 . The ApoE polymorphism (ε4+/ε4-) was evaluated in a subsample of 81 AD patients and 94 controls. The ApoE analysis was performed as previously described by Bahia et al.
11
.
To compare frequencies of genotypes and alleles, we used Pearson χ 2 test or Fisher's exact test when sample size was small. Sex distribution was compared between patients and controls using Pearson χ 2 test. Age and schooling distribution were compared using MannWhitney test. Kruskall-Wallis test was used to compare median between three or more groups. Logistic regression models were used to control for potential confounding effect of sex, age and schooling. Odds ratio (OR) and 95% confidence intervals (CI) were calculated from the logistic regression models. Statistical analyses were done using Stata 11.0 program. 
Ethics
This study was approved by the Ethics Committee for analysis of research projects (CAPPesq) of Hospital das Clínicas, School of Medicine, USP. Subjects signed the informed consent form. When patient had the diagnosis of moderate or severe dementia, the written informed consent was given by a close relative. The study was conducted in compliance with the Declaration of Helsinki.
RESULTS
The genotype distribution of codon 129 polymorphisms in the AD group was 45.5% MM, 42.2% MV, and 12.1% VV; and 39.6% MM, 50.5% MV, and 9.9% VV among controls. The genotype distributions were not statistically different between groups. Subgroup analysis according to age at onset revealed no difference of genotype distribution between patients with EOAD and LOAD and the respective control groups. The analysis of M and V allele frequency, as well as homozygosity and heterozygosity distribution did not significantly differ between AD and control groups. These results are displayed in Tab. 2. The genotype distributions were in Hardy-Weinberg equilibrium.
The genotype distribution at codons 117, 171 and octapeptide domain were not different between AD patients and controls (data not shown).
Concerning the cognitive evaluation, MMSE scores were significantly higher in AD patients with VV polymorphism and lower in patients with MM genotype (Table 3 ). The median time of disease was significantly shorter in VV patients and longer in MM patients. Logistic regression model did not confirm the association of MMSE performance and codon 129 polymorphism in AD group. There were no differences at VF test performance of AD patients as well as at MMSE and VF test performance of controls concerning the codon 129.
The stratification according to the ApoE genotype did not reveal any difference in the frequency of codon 129 polymorphism between AD and control groups ( Table 2) .
DISCUSSION
The codon 129 polymorphism of PRNP has been associated with AD and cognitive performance in the elderly population 19, 28 . Although reports show contradictory results, this polymorphism has been associated with different phenotypes in prion diseases and other neurodegenerative diseases [3] [4] [5] [6] [7] [8] . The homozygosity for V was associated with higher risk of cognitive impairment in two large populational studies 28, 29 . On the other hand, the homozygosity for M was also associated with lower scores on cognitive tests in cognitive normal population 30 . The evaluation of AD patients in populations worldwide shows divergent results. In an Italian sample, despite no difference between the frequency of codon 129 polymorphisms in AD patients, the presence of one V allele was related to phenotypic characteristics: earlier disease onset and more aggressive disease 16 . In another Italian report, only VV genotype was associated with a faster rate of cognitive decline 19 . Table 2 . Genotype, alleles, and homozygosity frequencies in cases and controls.
AD: Alzheimer's disease; EOAD: early-onset AD; LOAD: late-onset AD; M: methionine; V: valine; ApoE: apolioprotein E gene.
In a few European studies, codon 129 polymorphisms have been demonstrated to confer higher risk to AD. In a Dutch report, EOAD was more frequent in patients with family history of AD and codon 129 homozygosity, particularly VV 17 . The increased risk for EOAD was also demonstrated in MM patients in Germany 13 . In a Polish study, MM genotype was found to be a genetic risk factor only in LOAD 14 .
In Asian countries, all reported studies failed to demonstrate any association between the PRNP polymorphism at codon 129 and AD 18, 20, 31 . Of note, VV genotype is very rare in the Asian population 18, 31 . Our results are in line with most of the studies reported to date. We failed to find any association between the codon 129 polymorphisms of PRNP and AD, even when patients were divided in EOAD and LOAD. The frequency of the genotypes in the studied groups was similar to that previously described in a Brazilian population of blood donors: 45.6% MM, 48.2% MV, and 6.2% VV 32 . Our results are also in agreement with the unique neuropathologically supported data that refutes the association between codon 129 polymorphism and AD 8 . The patients described here presenting VV genotype scored better at MMSE, which is contradictory to other data showing that codon 129 homozygosity is associated with lower cognitive performance [28] [29] [30] . This result could be explained by the shorter period of disease of VV patients and not by the codon 129 polymorphism. This is particularly reinforced by the logistic regression analysis that refuted the association between MMSE performance and different genotypes at codon 129.
In opposition to some studies, which showed interaction between ApoE and PRNP, our data did not reveal differences in codon 129 genotypes according to the ApoE status [13] [14] [15] [16] [17] [18] [19] [20] [21] . This study of PRNP in patients with AD in the Brazilian population has, as its main limitation, the small sample. Additional studies would be necessary to confirm these negative results regarding the relationship between AD and the polymorphism at codon 129 of PRNP.
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